https://wallstreetanalyzer.com/2020/12/23/canaquest-medical-corp-otc-canqf/
Highlights in the discussion include significant milestones achieved by the Company:
The Announcement that
Mentabinol® could also be a viable treatment to help address and alleviate the opioid crisis.
Second Master Formulation
Mentanine®, Omega-3 + CBD, non-psychotic - crosses the Blood
Mentanine® has ~10x the efficacy of a CBD-based FDA-approved product by
- Looking to start clinical trials of Mentanine® as a treatment of epilepsy
- FDA-approval process expected to take 18 to 24 months
- Key difference vs other CBD products in the market - scientific formula supported by preclinical trials
- Company is looking to list on the CSE and up list in the US after a capital raise (currently on OTC Markets)
- Strong possibility for near term revenue, in advanced discussions with Licensed Processors and Distributors
About
As well, CanaQuest will be selling both products through its wholly owned subsidiary,
For a short video on the research, visit https://www.youtube.com/watch?v=O_D4wkHHbDg
For more information on CanaQuest, visit http://www.canaquest.com
About Wall Street Analyzer:
The Wall Street Analyzer http://www.wallstreetanalyzer.com/ is a multi-media financial research and publishing company reporting to the investment community on publicly held companies.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the
CANAQUEST CONTACT:
paul@canaquest.com:
Tel.: 416-704-3040
Source:
2021 GlobeNewswire, Inc., source